Application of glycine in acute alcohol hallucinosis.
BACKGROUND
Previous studies showed that patients with acute alcohol hallucinosis had significantly lower levels of the inhibitory amino acid neurotransmitter, glycine.


METHODS
A placebo-controlled, double-blind study of glycine in 40 patients with acute alcohol hallucinosis. Treatment duration was 7 days with no other psychotropic medication.


RESULTS
The 20 patients randomised to the active drug (700 mg glycine sublingually) demonstrated a significant decrease in severity of hallucinosis compared to the 20 patients receiving placebo.


CONCLUSIONS
The positive effects of glycine may be related to an altered balance between excitatory and inhibitory amino acid neurotransmitters.
Aliyev
Nadir A
NA
Dispensary of Mental Hygiene, Azerbaijan Republic.
Aliyev
Zafar N
ZN
D000286:Administration, Sublingual; D000328:Adult; D000437:Alcoholism / Q000150:complications; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005998:Glycine / Q000008:administration & dosage / Q000627:therapeutic use*; D018684:Glycine Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006212:Hallucinations / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D018579:Patient Selection; D013607:Tablets; D016896:Treatment Outcome
D018684:Glycine Agents; D013607:Tablets; D005998:Glycine